Bernard Coulie - Sep 12, 2022 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role
President and CEO, Director
Signature
/s/ Mike Ouimette, attorney-in-fact
Stock symbol
PLRX
Transactions as of
Sep 12, 2022
Transactions value $
-$255,847
Form type
4
Date filed
9/14/2022, 05:31 PM
Previous filing
Jul 13, 2022
Next filing
Dec 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Options Exercise $26K +12.5K +21.09% $2.08* 71.8K Sep 12, 2022 Direct
transaction PLRX Common Stock Sale -$282K -12.5K -17.42% $22.54 59.3K Sep 12, 2022 Direct F1, F2
holding PLRX Common Stock 449K Sep 12, 2022 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLRX Stock Option (right to buy) Options Exercise $0 -12.5K -4.03% $0.00 297K Sep 12, 2022 Common Stock 12.5K $2.08 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.69, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.